Mr. Mark Upsdell reports

RAPID DOSE THERAPEUTICS REPORTS FISCAL YEAR 2023 FINANCIAL RESULTS

Rapid Dose Therapeutics Corp. has released its financial results for the year ended Feb. 28, 2023.

The company is pleased to be able to report on its results for the fiscal year 2023 which ended Feb. 28, 2023.

Complete financial statements are available at SEDAR.

2023 operational highlights:

• The company established B2B (business-to-business) channel partner relationships during the year to sell their nutraceutical products in Canadian retail stores, leading to an expanded customer base.
• RDT entered into a pharmaceutical collaboration agreement with Skycare Compounding Labs to develop, manufacture and distribute QuickStrips containing active pharmaceutical ingredients. The initial product, Lidocaine, for the dental applications, was tested during the third and fourth quarters of the fiscal year with a launch date of May 1, 2023.
• RDT was contracted to formulate and develop an oral thin film strip containing nicotine as the active ingredient. The precommercialization project continues throughout the current fiscal year ending Feb. 28, 2024. The project generated $90,000 (U.S.) in consulting services revenue during the fourth quarter of the 2023 fiscal year.
• The company continued to experience regulatory approval hurdles and delays for product applications in Europe, United States and Canada. Subsequent to the year-end, approvals have been obtained for the distribution of nutraceutical and cannabis products in Canada.
• The company's research and development program, in collaboration with strategic partners, have developed patentable intellectual properties for filing in the current fiscal year ending Feb. 28, 2024.

About Rapid Dose Therapeutics Corp.

Rapid Dose is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.

We seek Safe Harbor.